GRIP Molecular

University of Minnesota

GRIP Molecular’s single-use biosensor and mobile app provides consumers highly accurate and comprehensive medical diagnostic information in minutes, anytime and anywhere. The patented solid-state electronic platform technology is easy to use and does not require chemical reagents or a separate reader. GRIP’s underlying technology can be applied to diagnose most diseases and health conditions. The first product will simultaneously detect and characterize the immune response to COVID-19, Influenza A/B and other common upper respiratory infections. Proof of concept has been completed and development is underway with initial product launch anticipated in 2023.


Edward Gillen, CEO, is a leader in the advancement of global healthcare via applied innovation. Expert at defining strategies that gain endorsement and funding, and the application of cross-functional team leadership that results in their successful implementation. 30-years of global medical device experience. Adept at general management, strategy creation and implementation, innovation, product development, business development, strategic marketing and fundraising.

Dr. Bruce Batten, President and Chief Scientific Officer, is a proven leader with a highly successful track record as both a scientist (Cell and Molecular Biologist) and business executive. Full time academic appointments include Harvard Medical School, Tufts Medical School, The Ohio State University School of Medicine. More than thirty years of general management experience as a senior executive at the Vice President/General Manager level or higher, including President/CEO/CSO and Founder in high technology industries serving the Biomedical and Healthcare Industries.

Dr. Caroline Popper, Chief Medical Officer, has 30 years’ experience in medical diagnostics and drug discovery, combined with extensive direct clinical experience. She has held many senior managerial and advisory positions with numerous global diagnostics companies, including BD, bioMerieux and MDS Proteomics. Caroline was also an attending physician at the Department of Emergency Medicine at Baltimore’s Johns Hopkins Hospital, where she completed residencies in internal medicine and pathology.

Richard Minicus, CFO, has over 30 years of experience in M&A, venture capital investment, and capital markets transactions. Rich worked for 21 years in medical technology business development with Becton Dickinson (BD) and Pfizer, and for 9 years in commercial and investment banking with Merrill Lynch Capital Markets and JP Morgan. Rich gained venture capital experience with both BD Ventures and Merrill Lynch Venture Capital, where he invested in a wide variety of emerging medical technology and life science companies. Rich earned his MBA at Harvard Business School and holds an MS in Biology from Fairleigh Dickinson University.

Stasia Ogden, General Counsel, has particular expertise in Intellectual Property Law. Stasia has over 20 years as a practicing attorney in law firms and major multi-national corporations and 9 years with Baxter Healthcare Corporation and 4 years with BD. Her focus on healthcare industry global IP strategy, transactions, licensing, litigation and global IP portfolio management. Stasia has a Juris Doctor degree from Georgetown University, an MBA from University of Missouri.